A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.

Trial Details

NCT ID
NCT06627647
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Rilvegostomig
  • Pembrolizumab
  • Carboplatin
  • Cisplatin
  • Pemetrexed
Locations (sample)
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Anaheim, California, United States|33.83529,-117.9145
  • Beverly Hills, California, United States|34.07362,-118.40036

Key Eligibility Criteria

  • Histologically or cytologically documented non-squamous NSCLC.
  • Stage IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment.
  • Absence of sensitizing EGFR mutations (including, but not limited to, exon 19 deletion and exon 21 L858R, exon 21 L861Q, exon 18 G719X, and exon 20…
  • Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogen…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →